Rapid Micro Biosystems (RPID) EBITDA (2020 - 2026)

Rapid Micro Biosystems has disclosed EBITDA across 7 years of filings, most recently posting -$13.9 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$13.9 million, down 18.79% year-over-year; the trailing twelve-month figure through Mar 2026 was -$49.6 million (down 4.81% YoY), and the FY2025 annual result was -$47.4 million, up 5.06% from the prior year.
• EBITDA came in at -$13.9 million for Q1 2026 at Rapid Micro Biosystems, down from -$12.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$10.2 million in Q4 2024 to a low of -$17.3 million in Q4 2022.
• The 5-year median for EBITDA is -$13.9 million (2026), against an average of -$13.6 million.
• Across the five-year window, EBITDA slumped 54.77% in 2022 and grew 29.39% in 2023, its largest moves.
• Rapid Micro Biosystems' EBITDA stood at -$17.3 million in 2022, then grew by 29.39% to -$12.2 million in 2023, then increased by 16.07% to -$10.2 million in 2024, then fell by 19.38% to -$12.2 million in 2025, then decreased by 13.44% to -$13.9 million in 2026.
• The last three EBITDA figures came in at -$13.9 million (Q1 2026), -$12.2 million (Q4 2025), and -$11.4 million (Q3 2025), per Business Quant data.